, China
146 views
/Freepik

Allianz Jingdong aims for profitability boost through refined risk selection

Its investment risk is expected to stay low.

Fitch Ratings expects China-based Allianz Jingdong General Insurance to improve profitability over the next two years as Allianz Jingdong focuses on refining underwriting risk selection and controlling expenses.

The ratings agency also expects the insurer to continue improving its financial performance whilst maintaining stable credit fundamentals, supported by its strategic role within the Allianz Group. 

The insurer reported a return on equity of 6.5% in 2024, up from 2.4% in 2023, lifting the three-year average ROE to 2.5%. The combined ratio also improved slightly to 103% in 2024, from 104% a year earlier.

The company’s capitalisation remains adequate, though Fitch notes the capital buffer is modest. 

Investment risk is expected to stay low. The Fitch-adjusted risky-assets ratio declined to 45% in 2024 from 47% in 2023, remaining well below the threshold for the rating level. 

The company reduced exposure to insurance asset-management products and shifted toward higher-yielding debt schemes.

Equity-type investments increased but remained limited. Fitch expects continued caution in managing counterparty and liquidity risks.
 

Follow the link s for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.